|
Aim: Neutralizing antibodies (nAbs) hold great potential to prevent and treat SARS-CoV-2 infections. We propose to clone and express monoclonal antibodies (mAbs) from the IgG+ B cells of convalescent patients directed against SARS-CoV2 Spike (S) protein. Their neutralizing capacity will be tested by using pseudovirus particles and virus infection assays. Finally, the B-cell epitopes will be characterized for the selected neutralizing antibodies (nAbs) by cryogenic electron microscopy (cryo-EM).